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Upon viral infection, the major defense mounted by the host immune system is activation of the interferon
(IFN)-mediated antiviral pathway, which is mediated by IFN regulatory factors (IRFs). In order to complete
their life cycle, viruses must modulate host IFN-mediated immune responses. Despite its association with
significant human health problems, activities of Epstein-Barr virus (EBV), a human tumor-inducing herpes-
virus, to evade host IFN-mediated innate immunity have not been well characterized. To search for EBV genes
that block IFN signal transduction, we carried out a screening of EBV open reading frames for their abilities
to block IFN-/-mediated luciferase expression upon Sendai virus infection. This screening demonstrates
that EBV LF2 tegument protein specifically interacts with the central inhibitory association domain of IRF7,
and this interaction leads to inhibition of the dimerization of IRF7, which suppresses IFN- production and
IFN-mediated immunity. This demonstrates a novel immune evasion mechanism of EBV LF2 in blocking
cellular IRF7-mediated innate immunity.
The innate immune response is the host’s front line of de-
fense against microbial infection (15). Central to the host an-
tiviral response is the production of type I interferon (IFN),
which is delicately regulated by members of the IFN regulatory
factor (IRF) family (5, 15, 21–23). This family has been impli-
cated in antiviral defense, immune regulation, cell growth reg-
ulation, and apoptosis (3, 18, 33). The distinguishing charac-
teristic of this family is the highly conserved, amino-terminal
DNA-binding domain (DBD). Two closely related members of
this family, IRF3 and IRF7, appear to be the main transducers
of virus-mediated signaling in the induction of type I IFN (19,
22, 23, 27, 35). The transcription activity of IRF3 and IRF7
depends on the C-terminal phosphorylation, mediated by IKK-
related kinases TBK1 and IKKε (12, 16, 36). Phosphorylation
triggers series of alterations in IRF3 and IRF7, including con-
formation change, dimerization through a unique C-terminal
domain known as the inhibitory associated domain (IAD), and
nuclear translocation. These alterations result in the binding of
DNA to IRF3 and IRF7 through their exposed DBD, which
ultimately activates type I IFN transcription (28, 30, 39).
While IRF3 is a ubiquitous protein, IRF7 is IFN inducible
and dominantly exists in lymphoid origin cells (1, 2, 4). Upon
viral infection, IFN-, whose expression is mainly regulated by
IRF3, is thought to produce first due to its ubiquitous expres-
sion. IFN-, upon binding to the IFN receptor, activates a
signal cascade that eventually results in the transcriptional
induction of hundreds of critical antiviral genes, including IFN-
inducible protein kinase R, 2,5-oligoadenylate synthetases,
TLR3, TLR7, and IRF7 (11, 35). The transcription of IFN-,
which is primarily regulated by IRF7, is highly activated as a
result of the upregulation of IRF7 gene expression. Subse-
quently, secreted IFN- induces another round of IFN recep-
tor-mediated signal transduction as a positive feedback mech-
anism.
Most viruses have evolved strategies to defend themselves
against host IFN responses (13, 15). These strategies include
inhibiting IFN signaling by downregulating JAK-STAT signal
molecule basal levels, suppressing particular molecular modi-
fications, and preventing molecular translocation. For exam-
ple, Ebola virus VP35 abolishes type I IFN production by
inhibiting IRF3 activation (6, 7). Within Kaposi’s sarcoma-
associated herpesvirus (KSHV), a prototype gamma-2 herpes-
virus, open reading frame 45 (ORF45) encodes a protein to
block type I IFN production by inhibiting the phosphorylation
and nuclear localization of IRF7 (40). In addition, KSHV
vIRF3, called latency-associated nuclear antigen 2 (LANA2),
was recently reported to significantly subvert type I IFN pro-
duction by physically binding to IRF7 (24). Herpes simplex
virus, a prototype alphaherpesvirus, encodes at least two mod-
ulators of IFN response, US11 and ICP34.5, which target a
similar IFN response pathway, the double-stranded RNA-de-
pendent protein kinase R pathway (8–10, 31).
* Corresponding author. Mailing address: Molecular Microbiology
& Immunology Department, University of Southern California, Keck
School of Medicine, 2011 Zonal Avenue, HMR Rm. 401, Los Angeles,
CA 90033. Phone: (323) 442-1713. Fax: (323) 442-1721. E-mail:
jaeujung@usc.edu.
 Published ahead of print on 5 November 2008.
1140
 o
n
 April 22, 2014 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
Epstein-Barr virus (EBV) is a ubiquitous DNA virus: 90% of
the human population is infected with it (25). After infection,
the virus will remain with the host for the rest of its life. EBV
primary infection leads to infectious mononucleosis, while
long-term exposure to EBV has no obvious symptoms in an
immunocompetent host. In addition, EBV associates with a
variety of tumors, including immunoblast lymphoma, Hodgkin’s
disease, nasopharyngeal carcinoma, Burkitt’s lymphoma, and
gastric carcinoma in immunocompromised AIDS patients and
organ transplant recipients under immunosuppressive treat-
ment (25, 26). This indicates EBV is under the tight control of
the host immune system. Two EBV proteins have been de-
scribed which significantly suppress adaptive immune re-
sponses (20, 34). EBV BGLF5 helps the virus escape host
T-cell recognition and elimination of the infected cell by shut-
ting off the expression of major histocompatibility complex
(MHC) class I and MHC class II genes (34). BNLF2a, an EBV
lytic cycle early protein, blocks MHC class I presentation
through inactivation of the TAP1/TAP2 peptide transporter to
impair CD8 T-cell response (20). EBV BZLF1 was recently
reported to negatively regulate IRF7, but the mechanism re-
mains unclear (17). Despite its association with various human
health problems, our knowledge of the EBV evasion strategy
against type I IFN-mediated host innate immunity is lacking,
especially compared to those of other herpesviruses.
To search for specific EBV genes that block IFN signal
FIG. 1. LF2 inhibits type I IFN production. A total of 150 EBV entry clones constructed by Juergen Hass were subcloned into a destination
vector called pCR3.1-flag/6xhis-dest to establish an EBV expression library by using Gateway LR Clonase (Invitrogen, San Diego, CA). Restriction
enzyme digestion and DNA sequencing confirmed all of the EBV clones in pCR3.1-flag/6xhis-dest. Viral protein expression was determined by
immunoblotting with anti-Flag antibody (Sigma, Saint Louis, MO). EBV LF2 sequence was then amplified from its entry clone and subcloned into
the V5-tagged pCDNA5/FRT/To vector (Invitrogen) between the BamHI and XhoI sites. (A) LF2 inhibits the IRF7-induced activity of type I IFN
promoters. 293T cells were transfected with a type I IFN (IFN-1, IFN-4, or IFN-6) promoter-directed luciferase (luc) reporter, Renilla
luciferase reporter, and IRF7 expression vectors along with increasing amounts of LF2 expression vector. At 24 h posttransfection, cells were
infected with 50 HA units of SeV for 12 h. At 24 h postinfection, luciferase activity was measured by a dual-luciferase reporter assay kit from
Promega Biotech (Madison, WI) and normalized to Renilla luciferase activity to standardize transfection efficiency. Results are the averages of four
independent experiments. Four hundred nanograms of Ebola virus VP35 (the far-right bar in the panels) was used as a positive control in the
experiment. (B) Suppression of SeV-induced IFN mRNAs by EBV LF2. A total of 1  105 293T cells were seeded into six-well plates before
transfection and subsequently transfected using IRF7 with or without LF2, followed by stimulation with 100 HA units of SeV for 12 h. Real-time
quantitative RT-PCR was performed to detect mRNA levels of type I IFN, as previously described (24). (C) Suppression of SeV-induced IFN-
production by EBV LF2. 293T cells were transfected with IRF7 expression vectors with or without LF2 expression vector. At 24 h posttransfection,
cells were infected with 100 HA units of SeV for an additional 12 h. To detect IFN- levels, cell culture media were collected for ELISA. The
KSHV vIRF3 was included as a control. The results are the average of three independent experiments. (D) LF2 does not affect the IRF3-induced
activation of ISRE promoter activity. 293T cells were transfected with an ISRE promoter-directed luciferase reporter and Renilla luciferase
reporter along with increasing amounts of LF2. Cells were then treated with 100 HA units of SeV for 12 h. Luciferase activity was measured as
described in Fig. 1A. Ebola virus VP35 was included as a control (shown by the last bar in the panel).
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transduction, we carried out a screening of EBV ORFs for
their abilities to block IFN-/-mediated luciferase expression
upon viral infection. To establish an EBV expression library,
150 EBV entry clones were subcloned into pCR3-Flag-His6
destination vectors using the Gateway system. Each viral clone
was examined by restriction enzyme digestion and DNA se-
quencing, while viral protein expression was determined by
immunoblot analysis (data not shown). To identify EBV pro-
teins that inhibit type I IFN production, 293T cells were trans-
fected with IRF7, IFN-6 promoter-directed luciferase re-
porter, and a transfectional control Renilla luciferase reporter
along with individual EBV expression clones, and were subse-
quently infected with 50 hemagglutinating (HA) units of Sen-
dai virus (SeV), a potent stimulus of type I IFN production. At
24 h postinfection, cells were harvested for reporter assays.
Ebola virus VP35, which has been shown to block IFN signal
transduction (6, 7), was included as a positive control. This
screening discovered that EBV LF2 significantly inhibited
SeV-induced activation of IFN-6 promoter activity. To deter-
mine whether the inhibitory ability of LF2 was general or
specific to IRF7, we tested its effects on the activation of
IFN-1, -4, and -6 promoters, which are regulated primarily by
cellular IRF7 (11, 19, 22, 23, 27, 35). The results showed that,
in a dosage-dependent manner, LF2 expression robustly sup-
pressed IRF7-induced activation of IFN-1, -4, and -6 pro-
moter activities (Fig. 1A). To further address the inhibition of
IFN promoter activity by LF2, we measured the mRNA levels
of type I IFNs in the presence or absence of LF2 expression. At
24 h posttransfection using IRF7, with and without EBV LF2,
293T cells were infected with SeV for 16 h and then harvested
for the isolation of total RNAs. Reverse transcription-PCR
was performed with equal amounts of total RNA to determine
the type I IFN mRNA levels. Upon SeV infection, a marked
increase of IFN-1, IFN-4, and IFN-6 mRNAs was detected
in cells transfected with IRF7 vector, whereas an increase was
minimal or undetectable in cells transfected with both IRF7
and LF2 (Fig. 1B). Furthermore, enzyme-linked immunosor-
bent assay showed that similar to KSHV vIRF3, EBV LF2
effectively suppressed IFN- secretion induced by SeV infec-
tion (Fig. 1C). These results indicate that EBV LF2 efficiently
blocks the IRF7-mediated activation of type I IFN expression.
While both IRF7 and IRF3 are critical transcription regu-
lators of type I IFN gene expression, IRF7 primarily activates
IFN-1, -4, -6, and -14 promoter activity and IRF3 induces
ISRE (IFN-stimulated responsive element) promoter activity
(11, 19, 22, 23, 35). We investigated whether LF2 expression
abrogated the IRF3-induced activation of ISRE promoter ac-
tivity. At 24 h posttransfection with ISRE promoter-directed
luciferase reporter with increasing amounts of LF2, 293T cells
were infected with SeV for 12 h and then harvested for a
luciferase assay. The results showed that, unlike its robust
abrogation of IRF7 transcriptional activity, LF2 demonstrated
no effect on IRF3-induced activation of ISRE promoter activ-
ity (Fig. 1D). In contrast, Ebola virus VP35 considerably sup-
pressed virus-induced ISRE promoter activity under the same
conditions (Fig. 1D). These results suggest that EBV LF2
specifically inhibits the activity of IRF7 but not IRF3.
Given the inhibitory effect of EBV LF2 on IRF7-induced
transcription, we tested the potential interaction of LF2 with
IRF7. At 48 h posttransfection with IRF7 and Flag-tagged LF2
expression vectors or Flag-tagged IRF7 and V5-tagged LF2
expression vectors, 293T cells were used for immunoprecipita-
tion (IP) with anti-Flag antibody, followed by immunoblotting
with anti-IRF7 or anti-V5 antibody, respectively. Co-IPs
showed efficient interaction between LF2 and IRF7 (Fig. 2A
and B). Despite a high degree of similarity with IRF7, IRF3
was not able to bind to LF2 under the same conditions (Fig.
2C). Taken together, these data demonstrate that LF2 specif-
ically interacts with IRF7, but not IRF3, and this interaction
most likely accounts for the ability of LF2 to block IRF7-
mediated activation of type I IFN expression.
Upon viral infection, IRF7 undergoes an infection-induced
serine phosphorylation within its carboxyl-terminal regulatory
domain. This modification subsequently stimulates protein
dimerization, nuclear retention, and interaction with transcrip-
tional coactivators, resulting in the activation of a robust re-
sponse comprised of a broad spectrum of IFN isotypes (28, 30).
As previously shown (12, 16, 36), expression of TBK1 and
IKKε kinases, which phosphorylate the carboxyl-terminal reg-
ulatory domain of IRF7, led to the activation of IRF7 tran-
scriptional activity, resulting in a dramatic increase of IFN-4
promoter activity (Fig. 3A). However, LF2 coexpression effec-
tively suppressed TBK1 or IKKε kinase-mediated activation of
IRF7 transcriptional activity (Fig. 3A). Under these condi-
tions, IKKε or TBK coexpression led to an almost complete
shift of IRF7 to its slow-migrating, phosphorylated form during
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(Fig. 3B). We found that LF2 had no effect on TBK- or IKKε-
mediated migration retardation of IRF7 (Fig. 3B). A mutation
of the C-terminal 477 and 479 serine residues of IRF7 to
FIG. 2. (A and B) LF2 interaction with IRF7. 293T cells were
transfected with IRF7 and/or Flag-LF2 (A) or Flag-IRF7 and/or V5-
LF2. At 48 h posttransfection, cells were harvested for IP with anti-
Flag antibody, followed by Western immunoblotting (WB) with anti-
IRF7 antibody (A) or anti-V5 antibody (B). (C) LF2 does not interact
with IRF3. 293T cells were transfected with Flag-LF2 and either V5-
IRF7 or V5-IRF3 for Co-IP as described above. WCL, whole-cell
lysates.
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negatively charged glutamic acid, called IRF7 S477D S479D,
has been shown to mimic TBK- or IKKε-mediated phosphor-
ylation, resulting in the constitutive activation of IRF7 tran-
scriptional activity (28, 30, 39). LF2 suppressed, in a dosage-
dependent manner, the transcriptional activity of IRF7 S477D
S479D as effectively as that of wild-type IRF7 (Fig. 3C). Fur-
thermore, LF2 did not affect IR7 nuclear translocation because
LF2 is localized in the nucleus as well (Fig. 4). Finally, despite
the fact that IRF7 undergoes a proteosomal degradation path-
way (38), LF2 expression did not affect IRF7 protein levels at
FIG. 3. LF2 expression does not affect IRF7 phosphorylation. (A) LF2 downregulates the IKKε- or TBK1-mediated activation of IRF7
transcriptional activity. 293T cells were transfected with an IFN-4 promoter-directed luciferase (luc) reporter, Renilla luciferase reporter, IRF7
vector, and IKKε (the upper panel) or TBK1 (the lower panel) vector along with increasing amounts of LF2 vector. Luciferase activity was
measured as described in Fig. 1A. The IRF7 expression level was monitored by immunoblot analyses (one example shown below). (B) LF2 does
not inhibit the IRF7 phosphorylation induced by IKKε or TBK1. 293T cells were transfected with Flag-IKKε or Flag-TBK1 and IRF7 with or
without Flag-LF2. Western immunoblot (WB) analysis was then performed with the appropriate antibodies. (C) LF2 impairs the activity of type
I IFN promoter activities induced by constitutively active IRF7 S477D S479D mutant. 293T cells were transfected with an IFN promoter (IFN-1,
IFN-4, or IFN-6)-directed luciferase reporter, Renilla luciferase reporter, and IRF7 S477D S479D along with increasing amounts of LF2.
Luciferase activity was measured as described in Fig. 1. KSHV vIRF3 was included as a control.
VOL. 83, 2009 NOTES 1143
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a detectable level (Fig. 5). These results collectively indicate
that LF2 interaction has no effect on IRF7 phosphorylation
and protein stability.
IRF7 consists of an N-terminal tryptophan repeat containing
a DBD, a transactivation domain, an IAD, and a C-terminal
regulatory domain (RD) (28, 30, 39). The virus-induced phos-
phorylation of IRF7 appears to relieve an intramolecular as-
sociation between two autoinhibitory domains and unmask the
N-terminal DBD and C-terminal IAD, resulting in the forma-
tion of homodimers through the IAD. IRF7 dimers subse-
quently translocate from the cytoplasm to the nucleus and
stimulate DNA binding and transcriptional activities (28, 30,
39). To test whether LF2 interaction blocked IRF7 dimeriza-
tion, glutathione S-transferase (GST)-IRF7 fusion and Flag-
IRF7 proteins were coexpressed in 293T cells along with in-
creasing amounts of V5-LF2. A GST pull-down assay showed
that GST-IRF7 and Flag-IRF7 homodimerization was appar- ently reduced upon LF2 expression, while GST-IRF7 and V5-
LF2 interaction increased under the same conditions (Fig. 6A).
Cells were transfected with a V5-LF2 expression vector and
GST-IRF7 fusions containing the DBD, activation domain
(AD), IAD, RD, or the full-length gene, followed by GST
pull-down. The pull-down assay showed that V5-tagged LF2
efficiently interacted with full length GST-IRF7 and GST-IAD
but not with GST, GST-DBD, GST-AD, and GST-RD (Fig.
6B). These results indicate that LF2 effectively inhibits IRF7
dimerization by interacting with the IAD of IRF7, which may
account for the impairment of IRF7-induced transcription.
IRF7 is a master regulator of innate immunity and also plays
an important role in the transition from innate immunity to
acquired immunity (22). Due to its essential role in host im-
FIG. 4. LF2 expression does not affect IRF7 nuclear translocation.
293T cells or HeLa cells were transfected with either Flag-tagged IRF7
alone or together with V5-tagged LF2. Cells then were infected with
SeV at 12 h posttransfection. Immunostaining was performed on fixed
cells at 6 h postinfection, and confocal microscopy was used to observe
the fluorescence.
FIG. 5. LF2 expression does not affect IRF7 protein level. 293T
cells were transfected with IRF7 vector and increasing amounts of
Flag-LF2 vector. Cells were collected for Western immunoblot (WB)
analysis to detect the expression levels of IRF7 and LF2 using the
appropriate antibodies.
FIG. 6. LF2 blocks the IRF7 dimerization by binding to the IAD of
IRF7. (A) LF2 blocks the IRF7 dimerization. 293T cells were trans-
fected with GST-IRF7 and Flag-IRF7 along with increasing amounts
of V5-LF2. GST pull-down (PD) was performed at 36 h posttransfec-
tion, followed by Western immunoblotting (WB) with anti-Flag or
anti-V5 antibody. Whole-cell lysates (WCL) were included in the im-
munoblot assay. (B) LF2 binds to the IAD of IRF7. IRF7 domains
have been shown in the schematic diagram. Each domain of IRF7 was
in-frame fused with mammalian GST. At 36 h postransfection with
GST-IRF7 fusion vector and V5-LF2 vector, 293T cells were harvested
for GST pull-down, followed by immunoblotting with anti-V5 anti-
body.
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munity, numerous viruses have developed various strategies to
downregulate IRF7 activation. ICP0, encoded by herpes sim-
plex virus and bovine herpesvirus 1, inhibits phosphorylation
by TBK1 and IKKε (29). In response to viral infection, a
KSHV immediate-early lytic protein encoded by ORF45 that is
a virion tegument protein binds to IRF7 and blocks its phos-
phorylation and accumulation in the nucleus, resulting in a
blockage of IFN- and IFN- transcription (40). In addition,
the KSHV RTA immediate-early lytic nuclear transcription
factor acts as an ubiquitin E3 ligase to promote the ubiquiti-
nation and degradation of IRF7 protein in a proteasome-de-
pendent manner (38). In addition, KSHV vIRF3 has been
recently shown to bind IRF7, which suppresses the DNA bind-
ing ability of IRF7 (24). Our present study adds EBV LF2 to
the expanding family of viral proteins that inhibit cellular IRF7
transcriptional activity through protein-protein interactions.
EBV-encoded dUTP nucleotidohydrolase (dUTPase) has
recently been reported to induce immune dysregulation in vivo
in mice (14). EBV LF1 (ORF10) and LF2 (ORF11) both
contain a dUTPase-like domain, suggesting the potential role
of a dUTPase-like domain for anti-IFN activity. However, our
preliminary study indicated that a dUTPase-like domain was
not required for the inhibition of type I IFN production by LF2
(unpublished data). In addition, EBV LF1 and LF2 do not
appear to be essential for viral replication in cell culture, since
the genomic region containing these sequences is deleted from
the EBV B95-8 strain frequently used to study viral replication
and immortalization. Furthermore, we also found that the LF2
gene of rhesus lymphocryptovirus, the virus most closely re-
lated to EBV (32, 37), efficiently downregulates IRF7-induced
transcription of type I IFN, suggesting genetic and functional
conservation of LF2 in these two viruses (unpublished data).
Construction of LF2-knockout rhesus lymphocryptovirus
would be useful in elucidating the functional significance of
LF2 as a type I IFN antagonist, therefore providing a better
understanding of whether and how LF2 contributes to success-
ful EBV infection and pathogenesis in vivo.
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